Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Clinical Trials, High Risk Prostate Cancer, Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05960578
Phase: PHASE2
Trial Summary: This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (T – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Washington
Acronym:

Pin It on Pinterest